Should we raise now, and which capital route gets us to the next milestone?

Start with the job the capital must do

A round label is not a milestone. Write down the specific change that additional capital would enable: a paid deployment, repeatable sales motion, product validation, manufacturing readiness or another decision-relevant result. Then ask what evidence an appropriate next decision-maker would need to see. These are possible examples, not standard requirements across companies.

Compare that plan with the time and resources already available. If existing runway can reach the milestone, raising immediately is one option to test against waiting. If it cannot, the financing question becomes which source can fund that particular gap on workable terms.

Five capital paths, five different questions

The routes below are not substitutes on identical terms. A company can combine or sequence them, but the availability, timing and conditions of each must be checked for its situation and jurisdiction.

Can this plan reach a meaningful next decision?

Some investors will test whether the proposed amount and likely runway can reach the stated milestone, whether the team can execute that plan, and whether the result would matter to a future investor or customer. Those are possible underwriting questions, not a universal checklist. If the round would end before the proof can be generated, increasing the investor list does not fix the capital plan.

Sequence the work, then the capital

Capital sources can sometimes follow one another. A grant might support eligible technical validation, while later equity finances commercial deployment; an angel round might bridge a clearly defined proof point before a larger institutional raise. Strategic capital can help if the partner's goals and terms fit the company's wider options. Each sequence depends on actual eligibility, timing, restrictions and commitments. Put the milestones and cash dates on one timeline, and check what must be true before each source becomes available.

What changes by business and stage?

B2B software between Seed and Series A

Illustrative situation: customers value the product, but sales still depend heavily on the founder. More money might hire a go-to-market team; an investor may instead need evidence that demand repeats beyond founder-led selling. The decision is whether capital is required to run that test and whether the proposed round can reach a result the next room will recognize. There is no universal ARR threshold that answers it.

Deep tech with grants and a commercialization choice

Illustrative situation: grants give a team time to finish technical work, while equity could accelerate deployment or a hardware path. The decision is what additional risk the equity removes sooner, whether the grant path can fund the same milestone, and which investor type can understand the remaining technical and commercial risk. Grant awards and investor interest are different forms of evidence.

When investor interest is already present

A stalled process can reflect different bottlenecks. An investor may see a proof gap or a room mismatch. A proposed raise may be too small or too slow to reach the milestone being promised. Or warm language may not have become an owned investment decision; test interest through behavior. None of these diagnoses follows from a single polite response. Compare the objections, decision owners and actual next steps across the process.

Four questions to take into the next decision

1. Which milestone would change a financing or commercial decision, and what evidence would show it happened?
2. What can current resources fund before that decision point?
3. For the remaining gap, which capital source fits the timing, constraints and type of risk?
4. Which investor room could plausibly underwrite the company at this point, and what would it still need to believe about the team and execution plan?

Related decisions